Glycosphingolipid Accumulation Inhibits Cholesterol Efflux via the ABCA1/Apolipoprotein A-I Pathway
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Cellular glycosphingolipid (GSL) storage is known to promote cholesterol accumulation. Although physical interactions between GSLs and cholesterol are thought to cause intracellular cholesterol "trapping," it is not known whether cholesterol homeostatic mechanisms are also impaired under these conditions. ApoA-I-mediated cholesterol efflux via ABCA1 (ATP-binding cassette transporter A1) is a key regulator of cellular cholesterol balance. Here, we show that apoA-I-mediated cholesterol efflux was inhibited (by up to 53% over 8 h) when fibroblasts were treated with lactosylceramide or the glucocerebrosidase inhibitor conduritol B epoxide. Furthermore, apoA-I-mediated cholesterol efflux from fibroblasts derived from patients with genetic GSL storage diseases (Fabry disease, Sandhoff disease, and GM1 gangliosidosis) was impaired compared with control cells. Conversely, apoA-I-mediated cholesterol efflux from fibroblasts and cholesterol-loaded macrophage foam cells was dose-dependently stimulated (by up to 6-fold over 8 h) by the GSL synthesis inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP). Unexpectedly, a structurally unrelated GSL synthesis inhibitor, N-butyldeoxynojirimycin, was unable to stimulate apoA-I-mediated cholesterol efflux despite achieving similar GSL depletion. PDMP was found to up-regulate ABCA1 mRNA and protein expression, thereby identifying a contributing mechanism for the observed acceleration of cholesterol efflux to apoA-I. This study reveals a novel defect in cellular cholesterol homeostasis induced by GSL storage and identifies PDMP as a new agent for enhancing cholesterol efflux via the ABCA1/apoA-I pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIG. 1 Cellular GSL accumulation inhibits apoA-I-mediated cholesterol efflux. Control human fibroblasts ( A and B ) and SLSD fibroblasts ( C ) were grown in medium containing 0.2 𝛍 Ci/ml [ 3 H]cholesterol and 10% FCS for 72 h. After the initial 24 h, either 40 𝛍 M LacCer ( A ) or 50 𝛍 M CBE ( B ) was added as described under 'Experimental Procedures.' After equilibration (in the presence of LacCer or CBE where appropriate), cells were incubated in DMEM containing 0.1% (w/v) BSA or in the same medium with the addition of 25 𝛍 g/ml apoA-I. Aliquots of the media were removed at times up to 8 h, and the percent cholesterol efflux was calculated by dividing [ 3 H]cholesterol released to the medium by the total [ 3 H]cholesterol in the cells after equilibration ( t = 0 h). A : f , BSA; H18554 , BSA + LacCer; ● , apoA-I; E , apoA-I + LacCer. B and C : white bars , BSA; black bars , apoA-I. Con , control, Sand , Sandhoff disease. Values are the means ± S.E. from triplicate cultures of a single experiment, representative of three. *, p < 0.05; **, p < 0.01 (significantly different from apoA-I-dependent cholesterol efflux under control conditions).](https://figures.cochat.ai/paper-figures/2672331950fa465498b7e05547bf27fc/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-1.png)
![FIG. 2 Influence of LacCer on fibroblast phospholipid efflux to apoA-I and cholesterol efflux to apoA-I, PLVs, or MBCD. A , fibroblasts were grown as described in the legend to Fig. 1 and treated with 40 𝛍 M LacCer as indicated prior to analysis of [ 3 H]cholesterol and 3 H-phospholipid efflux to apoA-I as described under 'Experimental Procedures.' B , [ 3 H]cholesterol efflux to PLVs (200 𝛍 g/ml total phospholipid) or MBCD (250 𝛍 M) was also assessed. Data were derived after 8 h of efflux. Values represent the means ± S.E. from triplicate determinations. **, p < 0.01 (significantly different from cells treated with apoA-I alone). Con , control.](https://figures.cochat.ai/paper-figures/49a8c010899f4270b44b286de6c62892/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-2.png)

![FIG. 4 Expression of ABCA1 mRNA and acyl-CoA:cholesterol acyltransferase-accessible cholesterol in fibroblasts derived from normal subjects and patients with Fabry disease, Sandhoff disease, or GM1 gangliosidosis. A , fibroblasts were grown in DMEM and 10% FCS until confluent and washed three times with PBS; the RNA was extracted; and ABCA1 mRNA was quantified by real-time PCR. B , fibroblasts were labeled with [ 3 H]cholesterol as described in the legend to Fig. 1, and the cholesterol and cholesteryl ester fractions were isolated by TLC. Where indicated, control ( Con ) fibroblasts were also treated with 40 𝛍 M LacCer. The cellular cholesteryl ester content is expressed as a percentage of the total cholesterol. Values are relative to control cells and represent the means ± S.E. from triplicate determinations. **, p < 0.01; ***, p < 0.001 (significantly different from control cells). amt. , amount; Sand , Sandhoff disease.](https://figures.cochat.ai/paper-figures/b0be1ff8348040f48f0ef2ffb73d4803/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-4.png)


![FIG. 7 PDMP promotes apoA-I dependent-cholesterol and phospholipid efflux. Fibroblasts were grown in DMEM containing [ 3 H]cholesterol or [ 3 H]choline, 10% FCS, and 10 𝛍 M PDMP as indicated for 72 h. Cells were then washed, equilibrated (in the presence of PDMP where appropriate), and incubated in DMEM containing 0.1% (w/v) BSA or in the same medium with the addition of 25 𝛍 g/ml apoA-I. Aliquots of the media were removed at the indicated times, and the percent cholesterol and phospholipid efflux was calculated as described in the legend to Fig. 1. Values are the means ± S.E. from triplicate cultures, representative of seven experiments. ● , apoA-I; E , apoA-I + 10 𝛍 M PDMP; f , BSA; H18554 , BSA + 10 𝛍 M PDMP.](https://figures.cochat.ai/paper-figures/74ff3edac767422998e7cf7c9ccb59fc/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-7.png)
![FIG. 8 PDMP does not promote cholesterol efflux to PLVs or MBCD. Fibroblasts were grown in DMEM containing [ 3 H]cholesterol and 10% FCS or in the same medium supplemented with 10 𝛍 M PDMP ( cross-hatched ) for 72 h. Cells were then washed, equilibrated (in the presence of PDMP where appropriate), and incubated in DMEM containing 0.1% (w/v) BSA or in the same medium with the addition of 25 𝛍 g/ml apoA-I. Cholesterol efflux in the presence of PLVs ( A ) or MBCD ( B ) was also assessed. Aliquots of the media were removed after 8 h, and the percent cholesterol efflux was calculated as described in the legend to Fig. 1. Values are the means ± S.E. from triplicate cultures, representative of two experiments for each condition. Con , control.](https://figures.cochat.ai/paper-figures/85a01e301ddc4e4d86b2cec2025af735/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-8.png)

![FIG. 10 Effect of PDMP on Triton-soluble and Triton-insoluble cholesterol distribution. A , fibroblasts were grown in DMEM and 10% FCS with 0.2 mCi/ml [ 3 H]cholesterol ( 3H-Chol. ) or the same medium supplemented with 2.5, 10, or 40 𝛍 M PDMP for 72 h. Cells were then washed and equilibrated (in the presence of PDMP where appropriate) for 16 h. The cells were extracted into cold Triton X-100, and the detergent-insoluble ( Insol. ; ● ) and detergent-soluble ( Sol. ; E ) cholesterol levels were measured as described under 'Experimental Procedures.' B , the data are expressed as percent insoluble cholesterol. Values are the means ± S.E. from triplicate cultures. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (significantly different from control conditions).](https://figures.cochat.ai/paper-figures/7cf2028a1b8a4a46a9cd80227601e115/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-10.png)
![FIG. 11 Effect of NB-DNJ on fibroblast GSL levels, cholesterol solubility, and apoA-I-mediated cholesterol efflux. A , fibroblasts were grown in DMEM and 10% FCS with [ 3 H]cholesterol ( 3H-Chol. ) or [ 3 H]choline in the presence of 50 𝛍 M NB-DNJ ( cross-hatched ) as indicated for 72 h. Cells were then washed and equilibrated (in the presence of NB-DNJ where appropriate) for 16 h. The cells were assayed for cell-surface GM1 expression by CTxB binding, Triton X-100-insoluble cholesterol ( TX-100 ), or 8-h [ 3 H]cholesterol efflux in DMEM containing 0.1% (w/v) BSA (control ( Con )) or in the same medium with the addition of 25 𝛍 g/ml apoA-I as described under 'Experimental Procedures.' B , the effect of NB-DNJ on phospholipid efflux to apoA-I was analyzed. Values are the means ± S.E. from triplicate cultures, representative of two experiments, p < 0.05; ***, p < 0.01 (significantly different from parallel conditions without NB-DNJ treatment).](https://figures.cochat.ai/paper-figures/903afe61be864e7897e1ebed7b84e4b9/glycosphingolipid-accumulation-inhibits-cholesterol-efflux-via-the-abca1-figure-11.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is consistent with previous observations that increasing mTORC1 signaling induced ROS production34, whereas inhibiting mTORC1 reduced ROS34–36.”
From Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis (2021) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldstein, J. L., Ho, Y. K., Basu, S. K., & Brown, M. S. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.1.333 · Cited by 2,448
Structure and Function of Sphingolipid- and Cholesterol-rich Membrane Rafts
Brown, D. A., & London, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.r000005200 · Cited by 2,344
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
Simons, K., & Ikonen, E. (2000) · Science · doi:10.1126/science.290.5497.1721 · Cited by 1,275
Wang, N., Lan, D., Chen, W., Matsuura, F., & Tall, A. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403506101 · Cited by 1,061
Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα
Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C., Edwards, P. A., & Tontonoz, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200367697 · Cited by 1,005
The ATP switch model for ABC transporters
Higgins, C. F., & Linton, K. J. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb836 · Cited by 748
The macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport
Kobayashi, T., Beuchat, M.-H., Lindsay, M., Frias, S., Palmiter, R. D., Sakuraba, H., Parton, R. G., & Gruenberg, J. (1999) · Nature Cell Biology · doi:10.1038/10084 · Cited by 620
Research works printed but not linked: 1
- Radin, 1993, Adv. Lipid Res., 26, 183
Cited by
Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism
Kim, M., Wainwright, H. C., Locketz, M., Bekker, L., Walther, G. B., Dittrich, C., Visser, A., Wang, W., Hsu, F., Wiehart, U., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000079 · Cited by 489
Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis
Tian, R., Abarientos, A., Hong, J., Hashemi, S. H., Yan, R., Dräger, N., Leng, K., Nalls, M. A., Singleton, A. B., Xu, K., et al. (2020) · doi:10.1101/2020.06.27.175679 · Cited by 414
Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis
Tian, R., Abarientos, A., Hong, J., Hashemi, S. H., Yan, R., Dräger, N., Leng, K., Nalls, M. A., Singleton, A. B., Xu, K., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00862-0 · Cited by 414
Lysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases
Marques, A. R. A., & Saftig, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.221739 · Cited by 224
Kim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191
Self-citationNormalizing glycosphingolipids restores function in CD4+ T cells from lupus patients
McDonald, G., Deepak, S., Miguel, L., Hall, C. J., Isenberg, D. A., Magee, A. I., Butters, T. D., & Jury, E. C. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69571 · Cited by 166
Developments in the treatment of Fabry disease
van der Veen, S. J., Hollak, C. E. M., Kuilenburg, A. B. P., & Langeveld, M. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12228 · Cited by 158
Cardiac Microvascular Pathology in Fabry Disease
Thurberg, B. L., Fallon, J. T., Mitchell, R. N., Aretz, T., Gordon, R. E., & O'Callaghan, M. W. (2009) · Circulation · doi:10.1161/circulationaha.108.841494 · Cited by 150
Frambach, S. J. C. M., de Haas, R., Smeitink, J. A. M., Rongen, G. A., Russel, F. G. M., & Schirris, T. J. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.017897 · Cited by 137
ATP‐binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro
Chan, S. L., Kim, W. S., Kwok, J. B., Hill, A. F., Cappai, R., Rye, K., & Garner, B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05433.x · Cited by 133
Self-citationAye, I., Singh, A. T., & Keelan, J. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.04.012 · Cited by 124
Chatterjee, S. B., Bedja, D., Mishra, S., Amuzie, C., Avolio, A. P., Kass, D. A., Berkowitz, D. E., & Renehan, M. (2014) · Circulation · doi:10.1161/circulationaha.113.007559 · Cited by 109
ABCA7 Mediates Phagocytic Clearance of Amyloid-β in the Brain
Fu, Y., Hsiao, J.-H. T., Paxinos, G., Halliday, G. M., & Kim, W. S. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160456 · Cited by 98
Self-citationCathepsin D, a Lysosomal Protease, Regulates ABCA1-mediated Lipid Efflux
Haidar, B., Kiss, R. S., Sarov-Blat, L., Brunet, R., Harder, C., McPherson, R., & Marcel, Y. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605095200 · Cited by 85
Active membrane cholesterol as a physiological effector
Lange, Y., & Steck, T. L. (2016) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2016.02.003 · Cited by 87
Biétrix, F., Lombardo, E., van Roomen, C. P. A. A., Ottenhoff, R., Vos, M., Rensen, P. C. N., Verhoeven, A. J., Aerts, J. M. F. G., & Groen, A. K. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.201673 · Cited by 73
Glaros, E. N., Kim, W. S., Wu, B. J., Suarna, C., Quinn, C. M., Rye, K., Stocker, R., Jessup, W., & Garner, B. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.12.023 · Cited by 70
Self-citationLipid homeostasis in macrophages – Implications for atherosclerosis
Schmitz, G., & Grandl, M. (2008) · Springer eBooks · doi:10.1007/112_2008_802 · Cited by 77
Glaros, E. N., Kim, W. S., Quinn, C. M., Jessup, W., Rye, K., & Garner, B. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700261-jlr200 · Cited by 60
Self-citationFilipin recognizes both GM1 and cholesterol in GM1 gangliosidosis mouse brain
Arthur, J. R., Heinecke, K. A., & Seyfried, T. N. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012633 · Cited by 60
Sterols and sphingolipids: Dynamic duo or partners in crime?
Gulati, S., Liu, Y., Munkacsi, A. B., Wilcox, L. J., & Sturley, S. L. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.03.003 · Cited by 63
Kiss, R. S., Ma, Z., Nakada‐Tsukui, K., Brugnera, E., Vassiliou, G., McBride, H. M., Ravichandran, K. S., & Marcel, Y. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600621200 · Cited by 58
Papagiannakis, N., Koros, C., Stamelou, M., Simitsi, A., Maniati, M., Antonelou, R. C., Papadimitriou, D. A., Dermentzaki, G., Moraitou, M., Michelakakis, H., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.012 · Cited by 55
Porubský, Š., Speak, A. O., Salio, M., Jennemann, R., Bonrouhi, M., Zafarulla, R., Singh, Y., Dyson, J., Luckow, B., Lehuen, A., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201483 · Cited by 53
Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities
Ingemann, L., & Kirkegaard, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r048090 · Cited by 48
Meikle, P. J., Mundra, P. A., Wong, G., Rahman, K., Huynh, K., Barlow, C. K., Duly, A. M. P., Haber, P. S., Whitfield, J. B., & Seth, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130346 · Cited by 43
Hepatic Glycosphingolipid Deficiency and Liver Function in Mice
Jennemann, R., Rothermel, U., Wang, S., Sandhoff, R., Kaden, S., Out, R., van Berkel, T. J. C., Aerts, J. M. F. G., der Vlugt, K. G., Sticht, C., et al. (2010) · Hepatology · doi:10.1002/hep.23545 · Cited by 48
Tangier disease: update for 2020
Hooper, A. J., Hegele, R. A., & Burnett, J. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000669 · Cited by 43
Fabry disease: Mechanism and therapeutics strategies
Li, X., Ren, X., Zhang, Y., Ding, L., Huo, M., & Li, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1025740 · Cited by 57
Roet, K. C. D., Franssen, E. H. P., de Bree, F. M., Essing, A. H. W., Zijlstra, S.-J. J., Fagoe, N. D., Eggink, H. M., Eggers, R., Smit, A. B., van Kesteren, R. E., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1002-13.2013 · Cited by 37
Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling
Binnington, B., Nguyen, L., Kamani, M., Hossain, D., Marks, D. L., Budani, M., & Lingwood, C. A. (2016) · Glycobiology · doi:10.1093/glycob/cwv084 · Cited by 37
Sphingolipid Synthetic Pathways are Major Regulators of Lipid Homeostasis
Worgall, T. S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0650-1_9 · Cited by 43
Basak, T., Varshney, S., Hamid, Z., Ghosh, S., Seth, S., & Sengupta, S. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.03.011 · Cited by 32
Mishra, S., Bedja, D., Amuzie, C., Foss, C. A., Pomper, M. G., Bhattacharya, R., Yarema, K. J., & Chatterjee, S. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.06.001 · Cited by 32
Sphingolipids: major regulators of lipid metabolism
Worgall, T. S. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328028fda3 · Cited by 32
Use of a Glycolipid Inhibitor to Ameliorate Renal Cancer in a Mouse Model
Chatterjee, S. B., Alsaeedi, N., Hou, J. C., Bandaru, V. V. R., Wu, L., Halushka, M. K., Пили, Р., Ndikuyeze, G. H., & Haughey, N. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063726 · Cited by 28
Glaros, E. N., Kim, W. S., Rye, K.-A., Shayman, J. A., & Garner, B. (2008) · Journal of Lipid Research · doi:10.1194/jlr.e800005-jlr200 · Cited by 28
Self-citationMyriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition
Glaros, E. N., Kim, W. S., & Garner, B. (2010) · Clinical Science · doi:10.1042/cs20090452 · Cited by 28
Self-citationIncreased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging
Argyriou, A., Dermentzaki, G., Papasilekas, T., Moraitou, M., Stamboulis, E., Vekrellis, K., Michelakakis, H., & Stefanis, L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.08.069 · Cited by 32
Li, H., Turley, S. D., Liu, B., Repa, J. J., & Dietschy, J. M. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800180-jlr200 · Cited by 26
Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice #
Bijl, N., van Roomen, C. P. A. A., Triantis, V., Sokolović, M., Ottenhoff, R., Scheij, S. S., van Eijk, M., Boot, R. G., Aerts, J. M. F. G., & Groen, A. K. (2008) · Hepatology · doi:10.1002/hep.22663 · Cited by 23
Hsiao, J.-H. T., Fu, Y., Hill, A. F., Halliday, G. M., & Kim, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074016 · Cited by 26
Self-citationModulation of amyloid precursor protein processing by synthetic ceramide analogues
Li, H., Kim, W. S., Guillemin, G. J., Hill, A. F., Evin, G. M., & Garner, B. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.012 · Cited by 23
Self-citationPsychotropic and Neurotropic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_6 · Cited by 24
Regulation of lipid metabolism by sphingolipids
Worgall, T. S. (2008) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-8830-8_14 · Cited by 23
Mechanistic convergence and shared therapeutic targets in Niemann‐Pick disease
Colaço, A., Kaya, E., Adriaenssens, E., Davis, L. C., Zampieri, S., Fernández‐Suárez, M. E., Tan, C. Y., Deegan, P. B., Porter, F. D., Galione, A., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12191 · Cited by 20
Good, C. J., Butrico, C. E., Colley, M. E., Emmerson, L. N., Gibson-Corley, K. N., Cassat, J. E., Spraggins, J. M., & Caprioli, R. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.09.005 · Cited by 26
Bijl, N., Scheij, S. S., Houten, S. M., Boot, R. G., Groen, A. K., & Aerts, J. M. F. G. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139394 · Cited by 19
microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance
Monchusi, B. A., & Kaur, M. (2020) · Genes & Cancer · doi:10.18632/genesandcancer.202 · Cited by 26
Lipid profile in adult patients with Fabry disease - Ten-year follow up
Stępień, K. M., & Hendriksz, C. J. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.06.010 · Cited by 11
Metabolic Pathway Genes Associated with Susceptibility Genes to Coronary Artery Disease
Lu, H., Chen, Y., & Li, L. (2018) · International Journal of Genomics · doi:10.1155/2018/9025841 · Cited by 12
Kim, W. S., Hill, A. F., Fitzgerald, M. L., Freeman, M. W., Evin, G. M., & Garner, B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110521 · Cited by 12
Self-citationThematic review series: Recent advances in the treatment of lysosomal storage diseases
Shayman, J. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.e049817 · Cited by 11
Chatterjee, S. B., Zheng, L., Ma, S., Bedja, D., Bandaru, V. V. R., Kim, G., Rangecroft, A., Iocco, D., & Campbell, S. A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.104 · Cited by 9
Sphingomyelin regulation of plasma membrane asymmetry, efflux and reverse cholesterol transport
Gulshan, K., & Smith, J. D. (2014) · Clinical Lipidology · doi:10.2217/clp.14.28 · Cited by 9
Schueler, U., Kaneski, C. R., Remaley, A. T., Demosky, S. J., Dwyer, N. K., Blanchette‐Mackie, J., Hanover, J. A., & Brady, R. O. (2015) · JIMD Reports · doi:10.1007/8904_2015_507 · Cited by 9
Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies
Hosseini, K., Fallahi, J., Tabei, K., & Razban, V. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3887 · Cited by 8
Elliott, D. A., Kim, W. S., Jans, D. A., & Garner, B. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.10.021 · Cited by 8
Self-citationLi, H., Evin, G. M., Hill, A. F., Hung, Y. H., Bush, A. I., & Garner, B. (2011) · Clinical Science · doi:10.1042/cs20110257 · Cited by 8
Self-citationThe role of sphingolipids in drug metabolism and transport
Kim, Y. M., Park, T., & Kim, S. G. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.748749 · Cited by 6
Animal Models of Neurological Disorders
Deshmukh, R., & Bansal, P. (2017) · Springer eBooks · doi:10.1007/978-981-10-5981-0 · Cited by 5
In situ lipidomics of Staphylococcus aureus osteomyelitis using imaging mass spectrometryPreprint
Good, C. J., Butrico, C. E., Colley, M. E., Gibson-Corley, K. N., Cassat, J. E., Spraggins, J. M., & Caprioli, R. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.01.569690 · Cited by 4
Sphingolipids and HDL Metabolism
Jiang, X., Li, Z., & Yazdanyar, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-407867-3.00006-8 · Cited by 5
Activation of ganglioside GM3 biosynthesis in human blood mononuclear cells in atherosclerosis
Gracheva, E. V., Samovilova, N. N., Golovanova, N. K., Piksina, G. F., Shishkina, V. S., & Prokazova, N. V. (2012) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750812030055 · Cited by 2
Animal Models of Neurological Disorders
Kallman, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-642-27728-3_33-2 · Cited by 2
Activation of ganglioside GM3 biosynthesis in human blood mononuclear cells in atherosclerosis
Gracheva, E. V., Samovilova, N. N., Golovanova, N. K., Piksina, G. F., Shishkina, V. S., & Prokazova, N. V. (2013) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20135904459 · Cited by 2
Lipidomics in Atherosclerotic Vascular Disease
Jänis, M. T., & Laaksonen, R. (2012) · Wiley eBooks · doi:10.1002/9783527655946.ch13 · Cited by 2
Endocrinological, immunological and metabolic features of patients with Fabry disease under therapy
Şanlı, M. E., Kılıç, A., İnci, A., Okur, İ., Ezgü, F. S., & Tümer, L. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0105 · Cited by 1
Leng, H., Zhang, H., Li, L., Zhang, S., Wang, Y., Ersek, A., Morris, E. V., Sezgin, E., Lee, Y., Li, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429906 · Cited by 1
Animal Models of Neurological Disorders
Kallman, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-05392-9_33 · Cited by 1
The role of glycosphingolipids in insulin signaling and lipid metabolism
Bijl, N. (2009) · UvA-DARE (University of Amsterdam)
Arsonists and Firefighters: The Perpetual Inflammatory Civil War for Survival
Karliner, J. S. (2014) · Circulation · doi:10.1161/circulationaha.114.010006
Retrovirus-mediated gene therapy for Farber disease.
Ramsubir, S. (2008) · TSpace (University of Toronto) · Cited by 1
Animal Models of Neurological Disorders
Kallman, M. J. (2015) · Springer eBooks · doi:10.1007/978-3-642-27728-3_33-1 · Cited by 1
Kuchler, T., Regenbogen, C., Günthner, R., Reiberio, A., Carbajo-Lozoya, J., Hannane, N., Wunderle, M., Assaf, A., Lech, M., Hanssen, H., et al. (2025) · medRxiv · doi:10.1101/2025.01.14.25320513
Charria-Ortiz, G. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-70909-3_15
Metadata
- Authors
- Glaros, E. N., Kim, W. S., Quinn, C. M., Wong, J., Gelissen, I., Jessup, W., & Garner, B.
- Affiliations
- UNSW Sydney (AU)
- Corresponding author
- Garner, Brett
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 280
- Issue
- 26
- Pages
- 24515-24523
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2134647594
- Cited by
- 75
- References
- 61
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 6 · 2013: 6 · 2012: 4
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5580 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Figshare (submittedVersion)
- Funders
- National Heart Foundation of Australia (222722)
- Medical Research Council
- National Health and Medical Research Council (350810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Keywords
- cholesterol efflux, ABCA1, apolipoprotein A-I, lactosylceramide, conduritol B epoxide, glucocerebrosidase, Fabry disease, Sandhoff disease, GM1 gangliosidosis, prescription drug monitoring programs, N-butyldeoxynojirimycin, cholesterol homeostasis, foam cells, fibroblasts
- MeSH terms
- Cell Line, Cell Membrane, Cholesterol, Chromatography, High Pressure Liquid, Dose-Response Relationship, Drug, Enzyme Inhibitors, Fibroblasts, Glycosphingolipids, Humans, Lactosylceramides, Lipoproteins, LDL, Monocytes, Morpholines, Phospholipids, RNA, Messenger, Time Factors, Blotting, Western, Antigens, CD, Up-Regulation, Apolipoprotein A-I, 1-Deoxynojirimycin, ATP-Binding Cassette Transporters, Biotinylation, Reverse Transcriptase Polymerase Chain Reaction, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.